Abstract Details

Title Multiple Sclerosis Symptom Recrudescence Is Common At The End Of The Natalizumab Dosing Cycle

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 213

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
John Ratchford, MD (Genentech) PRESENTER	Dr. Ratchford has received personal compensation for serving as an employee of Genentech. Dr. Ratchford has stock in F. Hoffman La-Roche.
	No disclosure on file
	No disclosure on file
Sonya U. Steele, MD (Johns Hopkins University)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ����